IGM Biosciences licenses SARS-CoV-2 antibodies from AvantGen
AvantGen has licensed a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.
Aldevron adds AAV plasmid product offerings
Aldevron has launched rep/cap plasmids to support adeno-associated virus (AAV) vector manufacturing.
AbSci acquires Denovium for protein AI platform
AbSci, a synthetic biology company, has acquired Denovium, an artificial intelligence (AI) deep-learning company.
ImmunityBio licenses oral vaccine tech from IosBio
ImmunityBio has signed an exclusive worldwide licensing agreement for IosBio's OraPro vaccine platform technology that is currently being investigated in trials of ImmunityBio's second-generation human adenovirus 5 (hAd5) COVID-19 vaccine candidate.
Berkeley Lights launches Opto Plasma B Discovery 4.0 workflow
Berkeley Lights has launched its Opto Plasma B Discovery 4.0 workflow for antibody discovery which can advance from B cells to lead molecules in one week.
Rocket Pharmaceuticals to build AAV manufacturing facility in NJ
Rocket Pharmaceuticals has announced the buildout for a new site in Cranbury, NJ, that will support Rocket's pipeline for lentivirus and adeno-associated virus (AAV) gene therapies.
Strand Therapuetics, BeiGene to develop mRNA platform tech
Strand Therapeutics and BeiGene have entered into an option and license agreement in order to develop and commercialize Strand's messenger RNA (mRNA) treatments for solid tumors.
Codagenix starts phase I trial for COVID-19 vaccine in U.K.
The first patient has been dosed in a phase I clinical trial being conducted by Codagenix and the Serum Institute of India of COVI-VAC, a single-dose, intranasal vaccine against the SARS-CoV-2 virus.
Istari wins orphan drug designation for melanoma therapy
The U.S. Food and Drug Administration has granted orphan drug designation to Istari Oncology for its PVSRIPO technology as a treatment for stage IIB-IV melanoma.
Immunocore closes $75M in series C round
Immunocore has completed $75 million in series C financing for the development of its novel T-cell receptor bispecific immunotherapies.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter